W
omen who regularly take the medication against osteoporosis, most common in the USA can stop their treatment for five years without risk of increasing fragility of bones, according to a study published yesterday.The study, published in the Journal of the American Medical Association could allow tens of millions of women menopauses in the world under treatment against osteoporosis (bone fragility occur after menopause), to stop taking Fosamax , A drug of U.S. pharmaceutical group Merck.
The study led by University of California, San Francisco was conducted from 1099 postmenopausal women suffering from osteoporosis and taking Fosamax for at least five years. Some have continued their treatment for five years with additional doses of 5 mg, 10 mg or a placebo.
Those who continued to take their medication, whatever the dose, have kept a bone density slightly higher than those taking a placebo. The latter have lost some bone density but not to increase their risk of fractures, said the study.
Previous Post :
